SciELO - Scientific Electronic Library Online

SciELO - Scientific Electronic Library Online

Article References

FERREIRA, Silvana Margarida Benevides; IGNOTTI, Eliane  and  GAMBA, Mônica Antar. Características clínico-laboratoriais no retratamento por recidiva em hanseníase. Rev. bras. epidemiol. [online]. 2012, vol.15, n.3, pp. 573-581. ISSN 1415-790X.  http://dx.doi.org/10.1590/S1415-790X2012000300011.

    1. World Health Organization. Leprosy update, 2011. (WHO) Weekly Epidemiological Record; 2011; 36(86): 389-400. [ Links ]

    2. World Health Organization. Global leprosy situation, 2010. (WHO) Weekly Epidemiological Record; 2010; 35(85): 337-48. [ Links ]

    3. Secretaria de Saúde do Estado de Mato Grosso. Setor de vigilância epidemiológica. Dados sobre Hanseníase no Estado de Mato Grosso por municípios e Escritórios Regionais de Saúde (ERS/SES/MT); Mato Grosso (MT); 2011. [ Links ]

    4. Ignotti E, De Paula RC. Situação epidemiológica da hanseníase no Brasil: análise de indicadores selecionados no período de 2001 a 2010. In: Saúde Brasil 2010: Uma análise da situação de saúde e de evidências selecionadas de impacto de ações de vigilância em saúde. Ministério da Saúde. Secretaria de Vigilância em Saúde/MS; 2010: 186-202. [ Links ]

    5. Ferreira SB, Ignotti E, Gamba MA. Recidivas de casos de hanseníase no Estado de Mato Grosso. Rev Saúde Pública 2010; 44(4): 1-7. [ Links ]

    6. World Health Organization. Leprosy fact sheet. (WHO) Weekly epidemiological record 2010; 6 (85): 37-48. [ Links ]

    7. Pettit JH, Rees RJ. Sulphone resistance in leprosy. An experimental and clinical study. Lancet 1964; 2(7361): 673-4. [ Links ]

    8. Shepard CC. The experimental disease that follows the injection of human leprosy into food pads of mice. J Exp Med 1960: 112(3): 445-54. [ Links ]

    9. Matsuoka M, Budiawan T, Aye KS, Kyaw K, Tan EV, Cruz ED et al. The frequency of drug resistance mutations in Mycobacterium leprae isolates in untreated and relapsed leprosy patients from Myanmar, Indonesia and the Philippines. Lepr Rev 2007; 78(4): 343-52. [ Links ]

    10. World Health Organization. Drug resistance in leprosy: reports from selected endemic countries. Weekly Epidemiological Record 2009, 26(84): 261-8. [ Links ]

    11. Ministério da Saúde. Portaria N 3.125 de 7 de outubro de 2010. Aprova as Diretrizes para Vigilância, Atenção e Controle da hanseníase. Gabinete do Ministro/MS. Brasília (DF); 2010. [ Links ]

    12. Kaimal S, Thappa DM. Relapse in leprosy. Indian J Dermatol Venereol Leprol 2009; 75(2): 126-35. [ Links ]

    13. Azulay RD, Azulay DR, Azulay-Abulafia L. Dermatologia. 5. ed., rev. e atual. Rio de Janeiro: Guanabara Koogan; 2008. p. 322-46. [ Links ]

    14. Ridley DS, Jopling WH. Classification of leprosy according to immunity; a Five group system. Int J Leprosy 1966; 34; 255-73. [ Links ]

    15. Shetty VP, Wakade AV, Ghate SD, Pai VV, Ganapati RR, Antia NH. Clinical, histopathological and bacteriological study of 52 referral MB cases relapsing after MDT. Lepr Rev 2005; 76: 241-52. [ Links ]

    16. Norman G, Joseph G, Richard J. Relapse in Multibacillary Patients Treated with Multi-drug Therapy until Smear Negativity: Findings after Twenty Years. Int J Leprosy 2004; (72): 11- 6. [ Links ]

    17. Suite M. Relapse rates following leprosy multidrug therapy. West Indian Med J 2000; 49 (3): 210-211. [ Links ]

    18. Rodriguez G, Pinto R, Laverde C, Sarmiento M, Riveros A, Valderrama J et al. Recidivas postratamiento de la lepra multibacilar. Biomédica 2004; 24: 133-9. [ Links ]

    19. Fundação Instituto Brasileiro de Geografia e Estatística. Contagem populacional 2007. População recenseada e estimada, segundo os municípios de Mato Grosso. Rio de Janeiro; 2007. [ Links ]

    20. Gelber RH, Balagon MVF, Cellona RV. The relapse rate in MB leprosy patients treated with 2-years of WHO-MDT is not low. Int J Leprosy 2004; 72(4): 493-9. [ Links ]

    21. Shen J, Liu M, Zhang J, Su W, Ding G. Relapse in MB leprosy patients treated with 24 months of MDT in South West China: a short report. Lepr Rev 2006; 77: 219-24. [ Links ]

    22. Bakker MI, Hatta M, Kwenang A, Mosseveld PV, Faber WR et al. Risk factors for developing leprosy - a population-based cohort study in Indonesia. Lepr Rev 2006; 77: 48-61. [ Links ]

    23. El-Hassan LA, Khalil EA, El-Hassan AM. Socio-cultural aspects of leprosy among the Masalit and Hawsa in the Sudan. Lepr Rev 2002; 73: 20-8. [ Links ]

    24. Cellona RV, Balagon MVF, Dela Cruz E, Burgos JA, Abalos RM, Walsh GP, et al. Long-term efficacy of 2-year WHO multiple drug therapy (MDT) in multibacillary (MB) leprosy patients. Int J Leprosy 2003; 71(4): 308-19. [ Links ]

    25. Ali MK, Thorat DM, Subramanian M, Parthasarathy G, Selvaraj U, Prabhakar V. A study on trend of relapse in leprosy and factors influencing relapse. Indian J Lepr 2005; 77(2): 105-15. [ Links ]

    26. Ximenes RAA, Gallo MEN, Brito MFM. Retreatment in Leprosy: a case-control study. Rev Saúde Pública, 2007; 41(4): 632-7. [ Links ]

    27. Balagon MF, Cellona RV, Dela Cruz E, Burgos JA, Abalos RM, Walsh GP et al. Long-Term Relapse Risk of Multibacillary Leprosy after Completion of 2 Years of Multiple Drug Therapy (WHO-MDT) in Cebu, Philippines. Am J Trop Med Hyg 2009; 81(5): 895-9. [ Links ]

    28. Girdhar BK, Girdhar A, Kumar A. Relapses in multibacillary leprosy patients: effect of length of therapy. Lepr Rev 2000; 71: 144-53. [ Links ]

    29. Opromola DVA. Ação terapêutica das drogas anti-hansênicas e evidências de persistência microbiana nos casos paucibacilares. Editorial. Hansen Int 2004; 29(1): 1-3. [ Links ]

    30. Ferreira SB, Ignotti E, Gamba MA. Fatores associados à ocorrência de recidiva em Mato Grosso. Rev Saúde Pública 2011; 45(4): 756-64. [ Links ]

    31. Goulart IMB, Penna GO, Cunha G. Imunopatologia da hanseníase: a complexidade dos mecanismos da resposta imune do hospedeiro ao Mycobacterium leparae. Rev Soc Bras Med Trop 2002; 35(4): 365-75. [ Links ]

    32. Beiguelman B. Genética e hanseníase. Ciênc Saúde Coletiva 2002; 7(1): 117-28. [ Links ]

    33. Franceshi DNA, Mazini OS, Rudnick CCC, Sell AU, Tsuneto LT, Ribas ML et al. Influence of TNF and IL10 gene polymorphisms in the immunopathogenesis of leprosy in the south of Brazil. Int J Infect Dis 2009; 13: 493-8. [ Links ]

    34. Bührer-Sékula S, Cunha MGS, Foss NT, Oskam L, Faber WR, Klatser PR. Dipstick assay to identify leprosy patients who have an increased risk of relapse. Trop Med Int Health 2001; 6(4): 317-23. [ Links ]

    35. Katoch VM, Lavania M, Chauhan DS, Sharma R, Katochi K. Recent advances in molecular biology of leprosy. Indian J Lepr 2007; 79(2-3): 151-66. [ Links ]

    36. Bhatia AS, Katoch K, Narayanan RB, Ramu G, Mukherjee A, Lavania RK. Clinical and histopathological correlation in the classification of leprosy. Intl J Lepr Other Mycobact Dis 1993; 61: 433-8. [ Links ]

    37. Gonçalves SD, Sampaio RF, Antunes CMF. Fatores preditivos de incapacidades em pacientes com hanseníase. Rev Saúde Pública 2009; 43(2): 267-74. [ Links ]